Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-lnducible factor-1α axis

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1297-1307

  Pencreach, Erwan ^a,b   Guérin, Eric ^a,b   Nicolet, Céline ^a   Lelong Rebel, Isabelle ^c   Voegeli, Anne Claire ^b   Oudet, Pierre ^a,b   Larsen, Annette K ^d,e,f   Gaub, Marie Pierre ^a,b   Guenot, Dominique ^a  

^a Institut National de la Santé   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c CNRS   (France)

^d CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^e Inst Natl S et de la Rech U129   (France)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; HIF1A PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL STRAIN HCT116; CELL STRAIN HT29; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENCY; DRUG SENSITIVITY; ENZYME ACTIVATION; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; COLON TUMOR; DRUG EFFECT; DRUG SCREENING; GLYCOLYSIS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MAP KINASE SIGNALING SYSTEM; MICE; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 63149114714     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0889     Document Type: Article

References (49)

1. Warburg 0. On the origin of cancer cells. Science 1956;123:309-14.
2. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006:66: 8927-30.
3. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001; 12:363-9.
4. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
5. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-αto the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1: 247-55.
6. 2 homeostasis. Curr Opin Genet Dev 1998;8:588-94.
7. Brunelle JK, Bell EL, Quesada NPV1, et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 2005;1:409-14.
8. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14.
9. Avellino R, Romano S, Parasole R, et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005;106:1400-6.
10. Frost P, ShiY, Hoang B, Lichtenstein A. AK Tactivity regulates the ability of mTOR inhibitors to prevent an- giogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007;26:2255-62.
11. Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005;105:2527-34.
12. Sin SH, Roy D, Wang L, et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007;109:2165-73.
13. Del Bufalo D, Ciuffreda L.Trisciuoglio D, et al. Anti- angiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66: 5549-54.
14. Mayerhofer M, Aichberger KJ, Florian S, et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J 2005;19:960-2.
15. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/HIF-1α/VEGF signaling. Neoplasia 2006;8:394-401.
16. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006:5:671 -88.
17. Zhong H, De Marzo AM, Laughner E, et al. Overex- pression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
18. Kohne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23: 4856-65.
19. Taieb J, Artru P, Paye F, et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 2005;23:502-9.
20. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia- inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62:4316-24.
21. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase l-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64: 1475- 82.
22. IkenoueT, Kanai F, HikibaY, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65:4562-7.
23. Samuels Y Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
24. Freilinger A, Rosner M, Hanneder M, Hengstschl- ager M. Ras mediates cell survival by regulating tuberin. Oncogene 2007;27:2072-83.
25. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1α a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001:61:2911 -6.
26. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
27. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-14.
28. ErlerJT, Cawthorne CJ, Williams KJ, et al. Hypoxia- mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004;24:2875-89.
29. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 2003;22:3213-20.
30. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypox-ia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997;94: 8104-9.
31. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/ Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997;90:3322-31.
32. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-64.
33. Zagzag D, Krishnamaehary B, Yee H, et al. Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005; 65:6178-88.
34. Bertrand FE, Steelman LS, Chappell WH, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 2006;20:1254-60.
35. Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006;5: 2676-84.
36. Chiu T, Santiskulvong C, Rozengurt E. EGF receptor transactivation mediates ANG ll-stimulated mitogene- sis in intestinal epithelial cells through the PI3-kinase/ Akt/mTOR/p70S6K1 signaling pathway. Am J Physiol Gastrointest Liver Physiol 2005;288:G182-94.
37. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98: 10314-9.
38. +/- mice. Proc Natl Acad Sci US A 2001;98:10320-5.
39. Kang S, Bader AG. Vogt PK. Phosphatidylinositol 3- kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005;102:802-7.
40. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamyein/p70S6K1 pathway. Cancer Res 2007; 67:6325-32.
41. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ. Loss of Tsc1 orTsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 2003;63:5173-7.
42. Skeen JE, Bhaskar PT, Chen CC, et al. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORCI- dependent manner. Cancer Cell 2006;10:269-80.
43. lacopetta B, Russo A, Bazan V, et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 2006;17:842-7.
44. Kastrinakis WV, Ramchurren N, Rieger KM, et al. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 1995;11:647-52.
45. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006;126:107-20.
46. Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science 2006;312:1650-3.
47. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP Mechanism of action of camptothecin. Ann N Y Acad Sci 2000;922:1-10.
48. Ashcroft M,Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000;20:3224-33.
49. Magrini R, Bhonde MR, Hanski ML, et al. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 2002; 101:23-31.